Could direct liver infusion boost radiation therapy for neuroendocrine tumors?
NCT ID NCT04544098
First seen May 08, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This early-phase study tests if giving the drug Lutathera directly into the liver's main artery is safe and practical for people with neuroendocrine tumors that have spread mostly to the liver. Ten participants will receive two infusions, one into the liver artery and one into a vein, to compare effects. The goal is to see if this approach can better control tumor growth while reducing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.